



PRODUCT: **VITRAKVI®**

COMPANY: Bayer

ABOUT THE PRODUCT

Larotrectinib (trade name: VITRAKVI®) is a first-in-class tropomyosin receptor kinase (TRK) inhibitor to treat tumors that have a neurotrophic receptor tyrosine kinase (*NTRK*) gene fusion. This is the first small molecule treatment to receive a tumor-agnostic indication at the time of initial United States Food and Drug Administration (FDA) approval. Larotrectinib was granted a breakthrough therapy designation by the FDA.

Larotrectinib is indicated for the treatment of adult and pediatric patients with solid tumors that:

- have a neurotrophic receptor tyrosine kinase (*NTRK*) gene fusion without a known acquired resistance mutation;
- are metastatic or where surgical resection is likely to result in severe morbidity; and
- have no satisfactory alternative treatments or that have progressed following treatment.